Subscribe
shutterstock_446090386_cristian_gusa
Cristian Gusa / Shutterstock.com
30 January 2024BiotechnologyMarisa Woutersen

Force pharma companies to provide drugs for rare cancer trials, UK govt told

MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Novartis ends eight-year cancer drug dispute for $182m
7 December 2023   Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.
Americas
Cancer specialist to pay $83.4m over DNA sequencing infringement
16 November 2023   TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
Novartis ends eight-year cancer drug dispute for $182m
7 December 2023   Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.
Americas
Cancer specialist to pay $83.4m over DNA sequencing infringement
16 November 2023   TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology.

More on this story

Big Pharma
Novartis ends eight-year cancer drug dispute for $182m
7 December 2023   Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.
Americas
Cancer specialist to pay $83.4m over DNA sequencing infringement
16 November 2023   TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool